MedTrace Logo

Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction

NCT05537675 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-11-30

No results posted yet for this study

Summary

Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by 177Lutetium-DOTATATE might contribute to improve follow-up and treatment response of refractory meningiomas. This study aims to evaluate Standard Uptake Value mean (SUVmean) as a tumoral absorbed dose predictive predictive factor and propose semi-automated segmentation method to determine metabolic tumor volume with pretherapeutic 68-Gallium-DOTATOC PET.

Conditions

  • Refractory Meningioma

Interventions

OTHER

To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax

Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Anne-Sophie HUE, MSc · CHRU Nancy

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2022-11-06
Completion
2022-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537675 on ClinicalTrials.gov